Crypto Pulse—US Stocks

SummaryVertex Pharmaceuticals enters the second half of 2026 with a strong cystic fibrosis franchise, growing contributions from ALYFTREK, CASGEVY and JOURNAVX, a potentially valuable kidney-disease pipeline and a proposed $10 billion acquisition of Crinetics Pharmaceuticals.The core bullish argument is that Vertex can use durable CF cash flows to build several new commercial franchises. The core bearish argument is that most revenue remains concentrated in CF while new launches, clinical progra

SummaryVRTX and VRTXON provide exposure to the economic performance of Vertex Pharmaceuticals, but they are fundamentally different instruments.VRTX is the Nasdaq-listed common stock of Vertex Pharmaceuticals Incorporated. VRTXON is an Ondo tokenized stock traded against USDT on MEXC. VRTXON is designed to track the total-return economics of VRTX but is not the underlying share and does not provide direct ownership or shareholder voting rights.The choice between them depends on the user’s object

SummaryVRTXON is an Ondo tokenized stock designed to provide economic exposure linked to Vertex Pharmaceuticals stock, ticker VRTX. Eligible users can trade VRTXON against USDT through the VRTXON/USDT market on MEXC.Trading VRTXON is not the same as purchasing traditional VRTX shares through a securities broker. VRTXON does not provide direct ownership or direct shareholder voting rights in Vertex Pharmaceuticals. It also carries additional token, issuer, liquidity, exchange and stablecoin risks

SummaryVRTXON is an Ondo tokenized stock designed to provide eligible users with economic exposure linked to Vertex Pharmaceuticals Incorporated stock, ticker VRTX.VRTXON is not issued by Vertex Pharmaceuticals and is not the same legal instrument as a VRTX share. It does not make the holder a directly registered Vertex shareholder or provide a direct right to receive the underlying VRTX stock.Ondo describes its tokenized stocks as total-return tracking products backed by corresponding stocks, E

SummaryVertex Pharmaceuticals Incorporated is a global biotechnology company listed on the Nasdaq Global Select Market under the ticker VRTX. The company is best known for developing medicines that treat the underlying cause of cystic fibrosis, but its commercial portfolio now also includes CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX for moderate-to-severe acute pain.Vertex generated approximately $12.0 billion in total revenue in 2025 and guided for

AAPL 1-year price chart, up 57.01% over the period. Chart from TradingView.A high volume breakout candle meets a price target that has not caught up.Apple closed at $333.02, up 3.53% ($11.36) on the day, after a sharp intraday move pushed the stock to a fresh all time high. That is a notable reversal in tone. Over the five sessions before today, AAPL had actually drifted 0.11% lower, trading in a tight, listless range. Today broke that pattern in one candle.🚀 The Breakout CandleThe intraday cha

TSM 1-year price chart, up 68% over the period despite the recent pullback. Chart from TradingView. Short term signals have flipped bearish, but the long term trend has not broken yet.Taiwan Semiconductor Manufacturing Company closed at $403.41, down 2.93% ($12.17) on the day. That single session loss is not an isolated event. Zoom out to the past month and TSM is down 7.2% ($31.32), a meaningful pullback for a stock that spent most of the year grinding steadily higher. Zoom out further, to the

Inside the charts, indicators, and key levels traders are watching after INTC's post-earnings reversal Intel just had one of its roughest single sessions in recent memory. Shares closed at $92.32, down $7.91, or 7.89%, in a single day. That kind of move doesn't happen in a vacuum: it landed in the days following Intel's Q2 2026 earnings report on July 23, where the company beat estimates on both revenue and EPS, with AI-driven data center revenue up 59% year-over-year. The post-earnings pop that

Microsoft will report its fiscal fourth-quarter 2026 earnings after the U.S. market closes on Wednesday, July 29. The earnings call will begin at 2:30 p.m. Pacific Time, or 5:30 p.m. Eastern Time, according to Microsoft’s official announcement.Microsoft enters the report with strong Azure growth, rising Copilot adoption and a large commercial backlog. However, the market’s main question has changed. Investors already know that demand for cloud computing and AI infrastructure is strong. They now

Meta Platforms will report its second-quarter 2026 earnings after the U.S. market closes on Wednesday, July 29. The earnings call is scheduled for 1:30 p.m. Pacific Time, or 4:30 p.m. Eastern Time. The headline numbers are expected to remain strong. However, Meta’s Q2 2026 earnings report is no longer only about Facebook and Instagram advertising growth.Wall Street will also be looking for evidence that Meta’s rapidly expanding AI infrastructure budget can create new revenue, improve its adverti